Akebia Therapeutics (AKBA)
(Delayed Data from NSDQ)
$1.37 USD
-0.03 (-2.14%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $1.39 +0.02 (1.46%) 7:08 PM ET
2-Buy of 5 2
C Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.37 USD
-0.03 (-2.14%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $1.39 +0.02 (1.46%) 7:08 PM ET
2-Buy of 5 2
C Value A Growth C Momentum B VGM
Zacks News
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 6.67% and 14.05%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Will CTI BioPharma (CTIC) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
CTI BioPharma (CTIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Akebia Therapeutics (AKBA) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 71.43% and 14.14%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Plus (PSTV) delivered earnings and revenue surprises of -6.67% and 88.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
GSK's Daprodustat Drug for Anemia Due to CKD Gets FDA Nod
by Zacks Equity Research
GSK announces the FDA approval of daprodustat for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least four months.
Akebia Therapeutics (AKBA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -86.67% and 3.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Akebia Therapeutics (AKBA) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 174.19% and 158.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Akebia Therapeutics (AKBA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -29.63% and 39.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zoetis (ZTS) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of 8.20% and 0.88%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Akebia Therapeutics (AKBA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -21.21% and 23.61%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Are Options Traders Betting on a Big Move in Akebia (AKBA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Akebia (AKBA) stock based on the movements in the options market lately.
Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -6.25% and -2.66%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akebia Therapeutics (AKBA) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -70.00% and -11.93%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Akebia Therapeutics (AKBA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Akebia Therapeutics (AKBA) stock based on the movements in the options market lately.
New Strong Sell Stocks for May 12th
by Zacks Equity Research
AKBA, CNA, EBMT, FCEL, and HMPT have been added to the Zacks Rank #5 (Strong Sell) List on May 12, 2021
Akebia Therapeutics (AKBA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -36.36% and 19.43%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Akebia (AKBA) Files NDA for Vadadustat for Anemia Due to CKD
by Zacks Equity Research
Akebia (AKBA) submits new drug application for vadadustat to treat anemia due to chronic kidney disease in adult patients who are on dialysis as well as who are not on dialysis.
Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Akebia Therapeutics (AKBA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Akebia Therapeutics (AKBA) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Akebia (AKBA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Akebia (AKBA) stock based on the movements in the options market lately.
Akebia Therapeutics (AKBA) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -82.61% and -21.20%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?